[go: up one dir, main page]

PL2041270T3 - Wytwarzanie glikoprotein - Google Patents

Wytwarzanie glikoprotein

Info

Publication number
PL2041270T3
PL2041270T3 PL07796784T PL07796784T PL2041270T3 PL 2041270 T3 PL2041270 T3 PL 2041270T3 PL 07796784 T PL07796784 T PL 07796784T PL 07796784 T PL07796784 T PL 07796784T PL 2041270 T3 PL2041270 T3 PL 2041270T3
Authority
PL
Poland
Prior art keywords
glycoproteins
production
Prior art date
Application number
PL07796784T
Other languages
English (en)
Inventor
Daniel R Lasko
Stephan M Koza
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38645762&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2041270(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PL2041270T3 publication Critical patent/PL2041270T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07796784T 2006-07-13 2007-07-11 Wytwarzanie glikoprotein PL2041270T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83065806P 2006-07-13 2006-07-13
PCT/US2007/015767 WO2008008360A1 (en) 2006-07-13 2007-07-11 Production of glycoproteins
EP20070796784 EP2041270B1 (en) 2006-07-13 2007-07-11 Production of glycoproteins

Publications (1)

Publication Number Publication Date
PL2041270T3 true PL2041270T3 (pl) 2014-04-30

Family

ID=38645762

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12164058T PL2495307T3 (pl) 2006-07-13 2007-07-11 Wytwarzanie czynnika krzepliwości krwi IX o polepszonym wzorze glikozylacji
PL07796784T PL2041270T3 (pl) 2006-07-13 2007-07-11 Wytwarzanie glikoprotein

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12164058T PL2495307T3 (pl) 2006-07-13 2007-07-11 Wytwarzanie czynnika krzepliwości krwi IX o polepszonym wzorze glikozylacji

Country Status (23)

Country Link
US (1) US8129145B2 (pl)
EP (3) EP2495307B9 (pl)
JP (1) JP5401310B2 (pl)
KR (1) KR101495549B1 (pl)
CN (2) CN104878064A (pl)
AR (1) AR061976A1 (pl)
AU (1) AU2007272957B2 (pl)
BR (1) BRPI0714212B8 (pl)
CA (1) CA2657248C (pl)
DK (3) DK2495307T5 (pl)
ES (2) ES2668212T3 (pl)
HK (1) HK1214307A1 (pl)
HU (1) HUE039128T2 (pl)
IL (1) IL196252A (pl)
MX (1) MX2009000349A (pl)
PE (1) PE20081194A1 (pl)
PL (2) PL2495307T3 (pl)
PT (2) PT2495307T (pl)
RU (1) RU2463345C2 (pl)
SI (1) SI2495307T1 (pl)
TR (1) TR201807021T4 (pl)
TW (1) TW200812577A (pl)
WO (1) WO2008008360A1 (pl)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
RU2518289C2 (ru) 2006-09-13 2014-06-10 Эббви Инк, Способ получения антитела или его фрагмента с подпиткой (варианты)
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
EP2395077A1 (en) * 2006-11-03 2011-12-14 Wyeth LLC Glycolysis-inhibiting substances in cell culture
PT2115126E (pt) * 2007-03-02 2015-08-24 Wyeth Llc Utilização de cobre e glutamato na cultura de células para a produção de polipeptídeos
TW200902708A (en) * 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
US20090233334A1 (en) * 2008-03-11 2009-09-17 Excellgene Sa Cell cultivation and production of recombinant proteins by means of an orbital shake bioreactor system with disposable bags at the 1,500 liter scale
CN102257006A (zh) 2008-10-20 2011-11-23 雅培制药有限公司 使用a蛋白亲和层析分离和纯化抗体
SG195577A1 (en) 2008-10-20 2013-12-30 Abbott Lab Viral inactivation during purification of antibodies
EP3009447B1 (en) * 2009-07-24 2018-06-06 Dr. Reddy's Laboratories, Ltd. Production of erythropoiesis stimulating protein using metal ions
ES2887552T3 (es) * 2009-07-28 2021-12-23 Takeda Pharmaceuticals Co Composiciones y métodos para tratar la enfermedad de Gaucher
SG185014A1 (en) 2010-04-26 2012-11-29 Novartis Ag Improved cell cultivation process
RU2615448C2 (ru) * 2010-12-28 2017-04-04 Чугаи Сейяку Кабусики Кайся Описание способа культивирования животной клетки
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012147053A1 (en) 2011-04-29 2012-11-01 Biocon Research Limited A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
CA2842559A1 (en) 2011-07-20 2013-01-24 Zepteon, Incorporated Polypeptide separation methods
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
AU2013309506A1 (en) 2012-09-02 2015-03-12 Abbvie Inc. Methods to control protein heterogeneity
WO2014143205A1 (en) 2013-03-12 2014-09-18 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014170866A2 (en) * 2013-04-18 2014-10-23 Dr. Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased galactosylation content
KR102118240B1 (ko) * 2013-08-20 2020-06-03 레크 파마슈티칼스 디.디. 폴리펩티드의 α-아미드화 및/또는 C-말단 아미노산 분열의 제어를 위한 세포 배양 매질 및 방법
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10590455B2 (en) * 2014-02-25 2020-03-17 Dr. Reddy's Laboratories Limited Process for modifying galactosylation and G0F content of a glycoprotein composition by glutamine supplementation
SG11201606856SA (en) * 2014-02-27 2016-09-29 Hoffmann La Roche Modulation of cell growth and glycosylation in recombinant glycoprotein production
AU2015355087B2 (en) 2014-12-01 2020-04-09 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
KR102007930B1 (ko) 2014-12-31 2019-08-06 주식회사 엘지화학 재조합 당단백질의 글리코실화 조절 방법
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
ES2912300T3 (es) 2015-05-22 2022-05-25 CSL Behring Lengnau AG Procedimientos de preparación de factor von Willebrand modificado
WO2016196621A1 (en) 2015-06-01 2016-12-08 Biogen Ma Inc. Manganese supplementation for control of glycosylation in mammalian cell culture process
CN104894055B (zh) * 2015-06-15 2018-07-17 成都金凯生物技术有限公司 一种优化的细胞培养基、细胞培养方法及其在制备蛋白和抗体中的应用
KR101932137B1 (ko) * 2017-01-02 2018-12-24 연세대학교 산학협력단 당화 증강용 조성물 및 당화 증강된 단백질의 제조방법
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
ES2994759T3 (en) 2018-11-13 2025-01-30 Janssen Biotech Inc Control of trace metals during production of anti-cd38 antibodies
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
WO2021112926A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
WO2022204120A1 (en) * 2021-03-23 2022-09-29 Biogen Ma Inc. Reducing host cell impurities during recombinant protein production

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5078996A (en) 1985-08-16 1992-01-07 Immunex Corporation Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NO162160C (no) * 1987-01-09 1989-11-15 Medi Cult As Serumfritt vekstmedium, samt anvendelse derav.
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
SU1587450A1 (ru) * 1988-05-04 1990-08-23 Институт биоорганической химии АН БССР Способ разделени гликозилированной и негликозилированной форм пролактина биологического материала
US6048728A (en) * 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US5156964A (en) * 1990-08-16 1992-10-20 Cetus Corporation Methods for adapting cells for increased product production through exposure to ammonia
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
GB9022545D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5118816A (en) 1990-12-26 1992-06-02 American Cyanamid Company 2-aryl-5-(trifluoromethyl)-2-pyrroline compounds useful in the manufacture of insecticidal, nematocidal and acaricidal arylpyrroles
ATE447016T1 (de) 1991-01-21 2009-11-15 Elan Pharm Inc Prüfung und modell für alzheimers-krankheit
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE452207T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5571515A (en) 1994-04-18 1996-11-05 The Wistar Institute Of Anatomy & Biology Compositions and methods for use of IL-12 as an adjuvant
US5705364A (en) * 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
CN1868545A (zh) 1996-10-23 2006-11-29 宾夕法尼亚州立大学托管会 改良疫苗
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6217900B1 (en) 1997-04-30 2001-04-17 American Home Products Corporation Vesicular complexes and methods of making and using the same
CA2318379A1 (en) 1998-01-12 1999-07-15 Betagene, Inc. Identification of substances that modify cellular secretory function
JP2002504380A (ja) 1998-02-27 2002-02-12 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア ワクチン、免疫療法剤およびそれらの使用法
MXPA01003228A (es) 1998-09-30 2003-06-24 American Cyanamid Co Holotoxina de colera mutante como un coadyuvante.
ATE348173T1 (de) * 1999-04-26 2007-01-15 Genentech Inc Zellenzuchtverfahren für glycoproteine
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
IL151857A0 (en) 2000-03-22 2003-04-10 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
WO2002098368A2 (en) 2001-06-07 2002-12-12 Wyeth Holdings Corporation Mutant forms of cholera holotoxin as an adjuvant
AU2002322380B2 (en) 2001-06-07 2006-11-02 Government Of The United States Of America As Represented By The Uniformed Services University Of The Health Sciences Mutant forms of cholera holotoxin as an adjuvant
US8153768B2 (en) 2002-05-02 2012-04-10 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates
ATE359358T1 (de) 2002-07-15 2007-05-15 Immunex Corp Verfahren und medien zur kontrolle der sialysierung von proteinen, die von säugetierzellen produziert werden
US7335491B2 (en) * 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
US7294484B2 (en) * 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
AU2006312014A1 (en) 2005-11-02 2007-05-18 Wyeth Methods for adapting mammalian cells
EP3026109B1 (en) 2005-12-08 2022-03-09 Amgen Inc. Improved production of glycoproteins using manganese
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산

Also Published As

Publication number Publication date
BRPI0714212B8 (pt) 2021-05-25
MX2009000349A (es) 2009-03-09
CA2657248C (en) 2018-10-30
AR061976A1 (es) 2008-08-10
PL2495307T3 (pl) 2018-07-31
PT2041270E (pt) 2013-12-27
BRPI0714212A2 (pt) 2013-03-26
CN101541950A (zh) 2009-09-23
EP3255141A1 (en) 2017-12-13
EP2495307A1 (en) 2012-09-05
US20080081356A1 (en) 2008-04-03
PT2495307T (pt) 2018-05-10
DK3255141T3 (da) 2022-01-31
AU2007272957B2 (en) 2014-05-01
DK2495307T5 (en) 2018-07-16
EP3255141B1 (en) 2021-12-01
RU2463345C2 (ru) 2012-10-10
ES2668212T9 (es) 2018-05-30
DK2041270T3 (da) 2014-01-27
PE20081194A1 (es) 2008-09-22
RU2008152449A (ru) 2010-08-20
HUE039128T2 (hu) 2018-12-28
ES2668212T3 (es) 2018-05-17
CN104878064A (zh) 2015-09-02
CA2657248A1 (en) 2008-01-17
EP2495307B9 (en) 2018-05-02
TR201807021T4 (tr) 2018-06-21
KR101495549B1 (ko) 2015-02-25
KR20090029841A (ko) 2009-03-23
US8129145B2 (en) 2012-03-06
EP2495307B1 (en) 2018-02-21
HK1214307A1 (zh) 2016-07-22
IL196252A0 (en) 2011-08-01
BRPI0714212B1 (pt) 2021-01-19
DK2495307T3 (en) 2018-05-07
TW200812577A (en) 2008-03-16
ES2440487T3 (es) 2014-01-29
WO2008008360A1 (en) 2008-01-17
AU2007272957A1 (en) 2008-01-17
JP5401310B2 (ja) 2014-01-29
IL196252A (en) 2016-02-29
JP2009543550A (ja) 2009-12-10
EP2041270A1 (en) 2009-04-01
SI2495307T1 (en) 2018-05-31
EP2041270B1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
IL196252A0 (en) Production of glycoproteins
IL200030A0 (en) Improvement of protein production
ZA200809621B (en) Production of isoprenoids
EP2191397A4 (en) ENHANCED REJECTION OF NON-VOCABULARY WORDS
ZA201002000B (en) Production of isoprenoids
EP1899476A4 (en) CELLULASE PRODUCTION
GB0713895D0 (en) Production
EP2435577A4 (en) GLYCOPROTEIN PRODUCTION
GB0711697D0 (en) Method of manufacture
ZA200905728B (en) Production of glycoproteins with modified fucosylation
GB0605360D0 (en) Method of manufacture
GB0702695D0 (en) Production of vectors
PL2043838T3 (pl) Wytwarzanie płyt UHMPWE z polietylenu o ultra wysokiej masie cząsteczkowej
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
PL2133419T3 (pl) Zastosowania beta-dipeptydów cyjanoficyny
IL190914A0 (en) Production of dolasetron
EP2193864A4 (en) SYSTEM FOR PRODUCING AN ALLOY
EP2099924A4 (en) BIODIESEL PRODUCTION
ZA200900130B (en) Production of UHMWPE panels
GB0618649D0 (en) Production of amines
GB201114396D0 (en) Location of basesation
GB0712635D0 (en) Production of caseinate
GB0815433D0 (en) Manufacture of cast panels
SI2041270T1 (sl) Proizvodnja glikoproteinov
GB0816419D0 (en) Production of hydroelecticity